Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Antineoplastic Agents. Found 201 abstracts

no pagination
Murphy ME. The thousand doors that lead to death: p53-dependent repression and apoptosis. Cancer Biol Ther. 2003 Jul;2(4):381-2.
Townsend D, Tew K. Cancer drugs, genetic variation and the glutathione-S-transferase gene family. Am J Pharmacogenomics. 2003 Jan;3(3):157-72.
Treat J. Weekly topotecan in the management of lung cancer. Lung Cancer. 2003 Aug;41 Suppl 4:S27-31.
Chaturvedi P, Sudakin V, Bobiak ML, Fisher PW, Mattern MR, Jablonski SA, Hurle MR, Zhu Y, Yen TJ, Zhou BB. Chfr regulates a mitotic stress pathway through its RING-finger domain with ubiquitin ligase activity. Cancer Res. 2002 Mar 15;62(6):1797-801.
Cianfrocca M, Cooley TP, Lee JY, Rudek MA, Scadden DT, Ratner L, Pluda JM, Figg WD, Krown SE, Dezube BJ. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol. 2002 Jan;20(1):153-9.
Crul M, de Klerk GJ, Swart M, Weiner L, Palmer PA, Bol CJ, Beijnen JH, Schellens JH. Evaluation of the bioequivalence of tablets and capsules containing the novel anticancer agent R115777 (Zarnestra) in patients with advanced solid tumors. Eur J Drug Metab Pharmacokinet. 2002 Jan;27(1):61-5.
Davey MP. Cancer treatments. Imatinib mesylate. Clinical Journal of Oncology Nursing. 2002 Mar;6(2):118-20.
Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. The New England journal of medicine. 2002 Aug 15;347(7):472-80.
Entwistle JW, Goldberg M. Multimodality therapy for resectable cancer of the thoracic esophagus. Ann Thorac Surg. 2002 Mar;73(3):1009-15.
Held-Warmkessel J. What your patient needs to know about prostate cancer. Nursing. 2002 Dec;32(12):36-42; quiz N232.
Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol. 2002 Feb;29(1 Suppl 4):27-36.
Hudes G. Boosting bioavailability of topotecan: what do we gain?. J Clin Oncol. 2002 Jul;20(13):2918-9.
Kim S, Domon-Dell C, Wang Q, Chung DH, Di Cristofano A, Pandolfi PP, Freund JN, Evers BM. PTEN and TNF-alpha regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-kappaB-dependent pathway. Gastroenterology. 2002 Oct;123(4):1163-78.
Langer CJ. Elderly patients with lung cancer: biases and evidence. Current treatment options in oncology. 2002 Feb;3(1):85-102.
Ma J, Reed KA, Gallo JM. Cells designed to deliver anticancer drugs by apoptosis. Cancer Res. 2002 Mar;62(5):1382-7.
Ozols RF. Future directions in the treatment of ovarian cancer. Semin Oncol. 2002 Feb;29(1 Suppl 1):32-42.
Pan ZZ, Bruening W, Giasson BI, Lee VM, Godwin AK. Gamma-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways. The Journal of biological chemistry. 2002 Sep 20;277(38):35050-60.
Roberts JD, Smith MR, Feldman EJ, Cragg L, Grant S. Phase I study of bryostatin-1 and fludarabine in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. Clin Lymphoma. 2002 Dec;3(3):184-8.
Schuchter LM, Hensley ML, Meropol NJ, Winer EP. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2002 Jun 15;20(12):2895-903.
Shen M, Schilder RJ, Obasaju C, Gallo JM. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support. Cancer Chemother Pharmacol. 2002 Sep;50(3):243-50.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Antineoplastic Agents

Antineoplastic Agents Human therapeutic use drug therapy pharmacology drug effects Female Non-US Gov't Support administration & dosage metabolism US Gov't Support-PHS antagonists & inhibitors Middle Age physiology genetics pharmacokinetics Antineoplastic Combined Chemotherapy Protocols Male pathology Adult Apoptosis Neoplasms Radiotherapy blood Topotecan therapy Combined Modality Therapy Neoplasm Drug Resistance adverse effects Aged Ovarian Neoplasms Neoplasm Staging Promoter Regions (Genetics) Lung Neoplasms Lymphokines methods Neoplastic Gene Expression Regulation Oral Administration Randomized Controlled Trials Non-Small-Cell Lung Carcinoma Cell Survival Signal Transduction US Gov't Support-Non-PHS Cultured Tumor Cells Drug Administration Schedule Patient Education diagnosis Paclitaxel 80 and over Aged Squamous Cell Carcinoma Area Under Curve Endothelial Growth Factors Neoplasm Proteins Enzyme Inhibitors DNA Damage Biological Availability Cytoplasm Mass Screening Variation (Genetics) Tablets Small Cell Carcinoma Radiation-Protective Agents Enzyme Activation Protein p53 epidemiology Age Factors Survival Analysis Gelatinase B Intestinal Absorption Homeodomain Proteins MAP Kinase Signaling System Biological Therapy Amifostine surgery Drug Delivery Systems Remission Induction Androstadienes Capsules Breast Neoplasms NF-kappa B Chelating Agents Lymphocytic Leukemia-Chronic Local Neoplasm Recurrence Clinical Trials Nonparametric Statistics P-Glycoprotein ae [Adverse Effects] Gamma Rays Piperazines Half-Life Salvage Therapy pd [Pharmacodynamics] Drug Administration Protective Agents Hematopoietic Stem Cell Transplantation Prostatectomy dosage Protein-Tyrosine Kinase Prostatic Neoplasms Drug Interactions Tetracycline Molecular Chaperones etiology Withholding Treatment Treatment Outcome biosynthesis Glycoproteins cytology Cultured Cells ad [Administration and Dosage] nu [Nursing] Stress Myeloid Leukemia Amino Acid Sequence Mesna Epidermal Growth Factor Receptor Adenocarcinoma Esophagoscopy Cell Cycle Proteins ATP-Binding Cassette Transporters Adolescent Mutant Strains Mice Predictive Value of Tests Ligases radiation effects Androgen Antagonists radiotherapy Case Report Cell Cycle Isoquinolines Evidence-Based Medicine Carboplatin Immunologic Adjuvants Adjuvant Chemotherapy Genetic Transcription Oncologic Nursing Multiple Drug Resistance Polymorphism (Genetics) Tumor Suppressor Proteins Quinolones HT29 Cells Risk Factors Matrix Metalloproteinases Gastrointestinal Neoplasms Phosphoric Monoester Hydrolases Lactones Theoretical Models Razoxane Gelatinase A Forecasting
Last updated on Friday, January 03, 2020